This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders.

COVID-19 antibody therapeutic development - WHITEPAPER

ArticleImage

Download exclusive whitepaper

With the rapid spread of COVID-19 in 2020, there is a race to develop both a vaccine and therapies to treat the virus. Multiple traditional and off-the-shelf approaches are being clinically tested and validated for COVID-19 treatment: antibody-based therapies, existing drugs re-purposed for COVID-19, mRNA therapies and convalescent plasma from COVID-19 survivors. In this paper, we will evaluate the antibody therapies for COVID-19 currently in clinical trials and preclinical development.

To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content. Have any questions or interested in sponsoring future content? Email andrew.burrows@informa.com.

Log in or create an Informa Connect account to access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.